Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CCNK | O75909 | 4/20 | 0.37 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | DDO | Q99489 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | TPO | P07202 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LPO | P22079 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 2/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5005290 | 0.72 | DAO (0.36) | DAODDO | |
| SCHEMBL21528211 | 0.72 | CCNK (0.48) | CCNKCDK12FGFR1 | |
| SCHEMBL20536433 | 0.71 | MELK (0.37) | ADORA1 | |
| SCHEMBL21772947 | 0.71 | MELK (0.37) | ADORA1 | |
| SCHEMBL20536352 | 0.71 | DAO (0.33) | DAODDO | |
| SCHEMBL20535517 | 0.71 | DAO (0.33) | DAODDO | |
| SCHEMBL22674464 | 0.68 | ADORA1 (0.36) | ADORA1ADORA2ACCNKCDK12ALDH1A1 | |
| SCHEMBL27772928 | 0.67 | — | — | |
| SCHEMBL27794101 | 0.67 | — | — | |
| SCHEMBL15618545 | 0.67 | ADORA1 (0.42) | PDK2PDK4ADORA1ADORA2ACCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS INC (US) | 2020-03-05 | — | — | US | disclosed |
| WO-2018191587-A1 | TAM KINASE INHIBITORS | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071326-A1 | TAM KINASE INHIBITORS | PIK3CA, MAP3K1, MAP3K5 | PDK2 563/4885PDK4 964/4885ADORA1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.